In a first, MorphoSys, Incyte win Monjuvi FDA nod in lymphoma to challenge Roche’s Polivy

The FDA hasn’t specifically approved a therapy for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma after an initial line of therapy—until now. MorphoSys and Incyte’s Monjuvi—also known as tafasitamab—in combination with Celgene’s Revlimid now represents the first FDA-approved second-line regimen for DLBCL, the two companies said Friday. Because of Monjuvi’s importance… Read More »

Weekly Health Quiz: Insulin, Nutrients and Masks

1 Which of the following statements is accurate? While U.S. SARS-CoV-2 infection rates are rising, hospitalizations and death rates have steadily and dramatically declined for more than two months While U.S. SARS-CoV-2 infection rates are rising, as testing of healthy people continues to increase, hospitalizations and death rates have steadily and dramatically declined, demonstrating the… Read More »